HIGH PROBABILITY OF LONG-TERM SURVIVAL IN 2-YEAR SURVIVORS OF AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN FIRST OR SECOND COMPLETE REMISSION
| Autor: | Majhail, Navneet S., Bajorunaite, Ruta, Lazarus, Hillard M., Wang, Zhiwei, Klein, John P., Zhang, Mei-Jie, Rizzo, J. Douglas |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Transplantation Conditioning Adolescent Transplantation Autologous Article Disease-Free Survival Cohort Studies Young Adult Autologous hematopoietic cell transplantation hemic and lymphatic diseases Humans Overall survival Survivors Relapse Child Acute myeloid leukemia Relative mortality Remission Induction Hematopoietic Stem Cell Transplantation Middle Aged Survival Analysis Leukemia Myeloid Acute surgical procedures operative Treatment Outcome Female |
| Zdroj: | Bone marrow transplantation |
| ISSN: | 1476-5365 0268-3369 |
| Popis: | We describe long-term outcomes of autologous hematopoietic-cell transplantation (HCT) for 315 acute myeloid leukemia (AML) patients in first or second complete remission (CR). All patients were in continuous CR for ≥2-years post-HCT. Patients were predominantly transplanted in CR1 (78%) and had good or intermediate cytogenetic risk disease (74%). Median followup of survivors was 106 (range, 24-192) months. Overall survival at 10-years post-HCT was 94% (95% confidence intervals, 89-97%) and 80% (67-91%) for patients receiving HCT in CR1 and CR2, respectively. The cumulative incidence of relapse at 10-years post-HCT was 6% (3-10%) and 10% (3-20%) and that of non-relapse mortality was 5% (2-9%) and 11% (4-21%), respectively. On multivariate analysis, HCT in CR2 (vs. CR1), older age at transplantation and poor cytogenetic risk disease were independent predictors of late mortality and adverse disease-free survival. The use of growth factors to promote engraftment following HCT was the only risk factor for relapse. Relative-mortality of these 2-year survivors was comparable to that of age-, race- and gender-matched normal population. Patients who receive an autologous HCT for AML in CR1 or CR2 and remain in remission for ≥2-years have very favorable long-term survival. Their mortality rates are similar to that of the general population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|